Leadingpharm Facilitates Partners in Securing Multiple Approvals in Golden Autumn, Adding New Achievements!

In the golden autumn season, Leadingpharm, leveraging its outstanding capabilities and professional expertise, has achieved another remarkable success! From July to October, Leadingpharm successfully assisted its partners in obtaining the approval for upgrading 1 active pharmaceutical ingredient (API) to Category A, along with 11 marketing authorizations (MAs) for pharmaceutical preparations, further accelerating the process of drug market launch.
 

These approvals cover key therapeutic areas such as the urogenital system, oncology, cardiovascular system, respiratory system, gastrointestinal and metabolic system, and musculoskeletal system. The dosage forms involved include oral solutions, tablets, injections, and more. This fully demonstrates Leadingpharm's strong capabilities in the R&D and industrialization of complex dosage forms.

List of Approvals

Up to now, Leadingpharm has helped dozens of pharmaceutical companies successfully obtain marketing authorizations. Currently, it is closely following the latest review requirements, advancing high-quality and compliant submissions with a scientific and rigorous attitude. This ensures that every set of application materials can withstand professional review and every product meets quality standards. When clients choose Leadingpharm, they not only opt for the efficiency of "accelerated approval acquisition" but also the peace of mind brought by "zero quality deviation and controllable risks" throughout the entire drug R&D cycle.

The acquisition of each approval is a result of the joint efforts between Leadingpharm and its partners. We sincerely thank our partners for their trust, choice, and long-term support over the years, which have enabled us to move forward steadily on the path of pharmaceutical R&D and jointly create achievements that stand the test of both the market and time.
 

In the future, Leadingpharm will continue to uphold its corporate vision of "Enabling China's new drug technologies and manufacturing processes to keep pace with the world". It will further increase R&D investment, expand R&D fields, and enhance innovative R&D capabilities. Meanwhile, relying on its rich experience and professional advantages in drug R&D, clinical trials, and registration applications, Leadingpharm will continue to provide comprehensive, one-stop service support for its partners. It will work side by side with more partners to accelerate the market launch of more high-quality drugs.
 

—END—